<DOC>
	<DOCNO>NCT01100372</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposome-encapsulated doxorubicin citrate gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether liposome-encapsulated doxorubicin citrate effective give together without gemcitabine hydrochloride kill tumor cell . PURPOSE : This randomized phase II trial study liposome-encapsulated doxorubicin citrate give together gemcitabine hydrochloride see well work compare liposome-encapsulated doxorubicin citrate alone treat patient ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Liposome-Encapsulated Doxorubicin Citrate With Without Gemcitabine Hydrochloride Treating Patients With Ovarian Epithelial Cancer , Fallopian Tube Cancer , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess response rate liposome-encapsulated doxorubicin citrate gemcitabine hydrochloride versus liposome-encapsulated doxorubicin citrate alone patient platinum-refractory platinum-resistant ovarian epithelial , fallopian tube , primary peritoneal cavity cancer . Secondary - To assess quality life patient treat regimen . - To determine progression-free overall survival patient treat regimen . - To determine toxicity regimen . OUTLINE : This multicenter study . Patients stratify accord disease ( platinum-refractory disease v platinum-resistant disease . Patients randomize 1 2 treatment arm . - Arm I : Patients receive liposome-encapsulated doxorubicin citrate IV 60 minute day 1 gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive liposome-encapsulated doxorubicin citrate IV 60 minute day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients experience clinical benefit completion 6 course chemotherapy may continue therapy discretion investigator . Patients complete quality-of-life questionnaire ( EORTC-QLQ30 QLQ-OV28 ) baseline , , completion study therapy . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cavity cancer Progression recurrence firstline platinumbased chemotherapy ( platinumrefractory disease ) OR progression recurrence first 6 month follow end last platinumcontaining chemotherapy ( platinumresistant disease ) Meets ≥ 1 follow criterion : Measurable metastatic disease CT MRI scan , ultrasound , chest xray Evaluable disease CT/MRI scan ( e.g. , ascites pleural effusion ) chest xray ( e.g. , pleural effusion ) Tumor marker progression ( CA125 ) accord Rustin criterion , meet 1 follow criterion : CA125 &gt; 2 time upper limit normal ( UNL ) CA125 &gt; 2 time nadir value two occasion No ovarian carcinosarcoma ( malignant mixed Müllerian tumor ) pure sarcoma PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 3 month Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Neutrophil count ≥ 1.5 x 10³/mm³ Serum creatinine &lt; 1.5 time ULN Bilirubin &lt; 1.5 time ULN ( &lt; 2.5 time ULN liver metastasis present ) AST/ALT &lt; 2.5 time ULN ( unless cause parenchymal liver metastasis ) No childbearing capacity LVEF ≥ 50 % ECHO MUGA scan No significant comorbidity ( e.g. , uncontrolled infection , clinical sign cardiac insufficiency , history myocardial infarction , cardiac rhythmic disorder [ NYHA class IIIIV disease ] ) No know hypersensitivity study drug No active secondary malignant tumor within past 5 year ( e.g. , metastases primary breast cancer ) No condition ( medical , social , psychological ) , would prevent adequate followup PRIOR CONCURRENT THERAPY : No prior chemotherapy pegylated liposomal doxorubicin hydrochloride , anthracyclines , gemcitabine hydrochloride No concurrent tumorspecific therapy ovarian cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
</DOC>